Since its founding in 2015, the Company has raised $127 million in venture capital funding to back its AI-driven approach to map the molecular pathways that impact human longevity.

BioAge’s mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan. For additional information about BioAge, visit the company’s website at www.bioagelabs.com.